Pharmacoeconomics of cancer therapy

S. E. Beltz, Gary C Yee

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Background: In 1990, annual costs of the diagnosis and treatment of cancer reached nearly $100 billion and currently constitutes approximately 10% of breath care expenditures in the United States. As new and often more expensive therapies for cancer treatment become available, the health care decision-maker must consider the cost effectiveness of the therapy. Methods: Key principles of economic analyses and the inherent differences among these analyses are reviewed. Results: While pharmacoeconomic analyses are increasingly being used in treatment decision-making, several issues relating to study design, data collection, and research methods are controversial. Conclusions: Pharmacoeconomics analyses are necessary in the current health care environment, but the assumptions used within the analyses warrant careful evaluation.

Original languageEnglish (US)
Pages (from-to)415-424
Number of pages10
JournalCancer Control
Volume5
Issue number5
DOIs
StatePublished - Jan 1 1998

Fingerprint

Pharmaceutical Economics
Delivery of Health Care
Health Expenditures
Health Care Costs
Cost-Benefit Analysis
Neoplasms
Decision Making
Economics
Therapeutics
Research

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Pharmacoeconomics of cancer therapy. / Beltz, S. E.; Yee, Gary C.

In: Cancer Control, Vol. 5, No. 5, 01.01.1998, p. 415-424.

Research output: Contribution to journalReview article

Beltz, S. E. ; Yee, Gary C. / Pharmacoeconomics of cancer therapy. In: Cancer Control. 1998 ; Vol. 5, No. 5. pp. 415-424.
@article{850bb555b1374da696aaca30fce5ff9c,
title = "Pharmacoeconomics of cancer therapy",
abstract = "Background: In 1990, annual costs of the diagnosis and treatment of cancer reached nearly $100 billion and currently constitutes approximately 10{\%} of breath care expenditures in the United States. As new and often more expensive therapies for cancer treatment become available, the health care decision-maker must consider the cost effectiveness of the therapy. Methods: Key principles of economic analyses and the inherent differences among these analyses are reviewed. Results: While pharmacoeconomic analyses are increasingly being used in treatment decision-making, several issues relating to study design, data collection, and research methods are controversial. Conclusions: Pharmacoeconomics analyses are necessary in the current health care environment, but the assumptions used within the analyses warrant careful evaluation.",
author = "Beltz, {S. E.} and Yee, {Gary C}",
year = "1998",
month = "1",
day = "1",
doi = "10.1177/107327489800500504",
language = "English (US)",
volume = "5",
pages = "415--424",
journal = "Cancer Control",
issn = "1073-2748",
publisher = "H. Lee Moffitt Cancer Center and Research Institute",
number = "5",

}

TY - JOUR

T1 - Pharmacoeconomics of cancer therapy

AU - Beltz, S. E.

AU - Yee, Gary C

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Background: In 1990, annual costs of the diagnosis and treatment of cancer reached nearly $100 billion and currently constitutes approximately 10% of breath care expenditures in the United States. As new and often more expensive therapies for cancer treatment become available, the health care decision-maker must consider the cost effectiveness of the therapy. Methods: Key principles of economic analyses and the inherent differences among these analyses are reviewed. Results: While pharmacoeconomic analyses are increasingly being used in treatment decision-making, several issues relating to study design, data collection, and research methods are controversial. Conclusions: Pharmacoeconomics analyses are necessary in the current health care environment, but the assumptions used within the analyses warrant careful evaluation.

AB - Background: In 1990, annual costs of the diagnosis and treatment of cancer reached nearly $100 billion and currently constitutes approximately 10% of breath care expenditures in the United States. As new and often more expensive therapies for cancer treatment become available, the health care decision-maker must consider the cost effectiveness of the therapy. Methods: Key principles of economic analyses and the inherent differences among these analyses are reviewed. Results: While pharmacoeconomic analyses are increasingly being used in treatment decision-making, several issues relating to study design, data collection, and research methods are controversial. Conclusions: Pharmacoeconomics analyses are necessary in the current health care environment, but the assumptions used within the analyses warrant careful evaluation.

UR - http://www.scopus.com/inward/record.url?scp=0031769098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031769098&partnerID=8YFLogxK

U2 - 10.1177/107327489800500504

DO - 10.1177/107327489800500504

M3 - Review article

C2 - 10761091

AN - SCOPUS:0031769098

VL - 5

SP - 415

EP - 424

JO - Cancer Control

JF - Cancer Control

SN - 1073-2748

IS - 5

ER -